Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sonnet BioTherapeutics Q3 EPS $(0.95) Misses $(0.49) Estimate

Author: Benzinga Newsdesk | August 14, 2025 02:41am
Sonnet BioTherapeutics (NASDAQ:SONN) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.49) by 93.88 percent. This is a 83.04 percent increase over losses of $(5.60) per share from the same period last year.

Posted In: SONN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist